Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pregabalin,Nortriptyline
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Launch of AFD-NP Product for Neuropathic Pain Management
Details : AFD-NP is a combination of Nortriptyline and Pregabalin which has approved for the treatment of moderate to severe neuropathic pain.
Product Name : AFD-NP
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) : Pregabalin,Nortriptyline
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lupin Completes Acquisition of Brands from Anglo-French
Details : The acquisition will strengthen Lupin’s business by adding a portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the AFDIL brands takes Lupin further in shaping its portfolio to emerge as a leading pharmaceutical ...
Product Name : Beplex Forte
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 04, 2022
Lead Product(s) : Nicotinamide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
